Efficacy and safety of ixazomib-based therapy for multiple myeloma
10.3760/cma.j.cn115356-20220111-00016
- VernacularTitle:伊沙佐米为基础方案治疗多发性骨髓瘤效果及安全性观察
- Author:
Mingxiao YU
1
;
Haihui LIU
;
Saisai REN
;
Chunyan YANG
;
Qian HUANG
;
Yanling TAO
;
Hao ZHANG
Author Information
1. 济宁医学院研究生院，济宁 272000
- Keywords:
Multiple myeloma;
Treatment outcome;
Ixazomib
- From:
Journal of Leukemia & Lymphoma
2022;31(4):209-212
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of ixazomib-based therapy for multiple myeloma.Methods:The data of 32 patients with multiple myeloma treated with isazomib-based regimen in the Affiliated Hospital of Jining Medical University from December 2020 to December 2021 were retrospectively analyzed. Among 32 patients, 17 cases were relapsed/refractory, and the remaining 15 cases had initial treatment. The treatment regimens included ID (isazomib + dexamethasone), IRD (isazomib + lenalidomide + dexamethasone) and ICD (isazomib + cyclophosphamide + dexamethasone). The short-term curative effect and adverse reactions of relapsed/refractory patients and patients at initial onset were analyzed.Results:The overall response rate (ORR) of relapsed/refractory patients was 52.9% (9/17), of which 6 cases achieved complete remission (CR), 2 cases achieved very good partial remission (VGPR) and 1 case achieved partial remission (PR). The ORR of refractory patients receiving bortezomib therapy was 40.0% (4/10). The ORR of patients at initial onset who could be evaluated the curative effect was 100.0% (14/14), including 9 cases of CR, 2 cases of VGPR and 3 cases of PR. After treatment, 2 patients (6.2%) had grade Ⅲ-Ⅳ adverse events (1 case of herpes zoster and 1 case of thrombocytopenia), and none of the patients had grade Ⅲ-Ⅳ peripheral neuropathy.Conclusion:Isazomib is effective and safe in the treatment of initially treated and relapsed/refractory multiple myeloma.
